Recent advancements in mesoporous silica nanoparticles towards therapeutic applications for cancer

Tingting Li; Sixiang Shi; Shreya Goel; Xue Shen; Xiaoxue Xie; Zhongyuan Chen; Hanxi Zhang; Shun Li; Xiang Qin; Hong Yang; Chunhui Wu; Yiyao Liu

doi:10.1016/j.actbio.2019.02.031

Recent advancements in mesoporous silica nanoparticles towards therapeutic applications for cancer

Acta Biomater. 2019 Apr 15:89:1-13. doi: 10.1016/j.actbio.2019.02.031. Epub 2019 Feb 20.

Authors

Tingting Li¹, Sixiang Shi², Shreya Goel³, Xue Shen⁴, Xiaoxue Xie⁴, Zhongyuan Chen⁴, Hanxi Zhang⁴, Shun Li⁵, Xiang Qin⁵, Hong Yang⁵, Chunhui Wu⁵, Yiyao Liu⁶

Affiliations

¹ School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, Sichuan, PR China; Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; Center for Information in Biology, University of Electronic Science and Technology of China, Chengdu 610054, Sichuan, PR China.
² Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
³ Department of Materials Science & Engineering, University of Wisconsin-Madison, Madison, WI 53705, USA.
⁴ School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, Sichuan, PR China.
⁵ School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, Sichuan, PR China; Center for Information in Biology, University of Electronic Science and Technology of China, Chengdu 610054, Sichuan, PR China.
⁶ School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, Sichuan, PR China; Hospital of Chengdu University of Traditional Chinese Medicine, No.39 Shi-er-qiao Road, Chengdu 610072, Sichuan, PR China. Electronic address: liuyiyao@uestc.edu.cn.

PMID: 30797106
DOI: 10.1016/j.actbio.2019.02.031

Abstract

Recently, drug delivery systems based on nanotechnology have received great attention in cancer therapeutics and diagnostics since they can not only improve the treatment efficacy but also reduce the side effects. Among them, mesoporous silica nanoparticles (MSNs) with large surface area, high pore volume, tunable pore size, abundant surface chemistry, and acceptable biocompatibility exhibit unique advantages and are considered as promising candidates for cancer diagnosis and therapy. In this review, we update the recent progress on MSN-based systems for cancer treatment purposes. We also discuss the drug loading mechanism of MSNs, stimuli-responsive drug release, and surface modification strategies for improving biocompatibility, and targeting functionalities. STATEMENT OF SIGNIFICANCE: The development of MSN-based delivery systems that can be used in both diagnosis and treatment of cancer has attracted tremendous interest in the past decade. MSN-based delivery systems can improve therapeutic efficacy and reduce cytotoxicity to normal tissue. To further improve the in vivo properties of MSNs and potential translation to the clinics, it is critical to design MSNs with appropriate surface engineering and desirable cancer targeting. This review is intended to provide the readers a comprehensive background of the vast literature till date on silica-based drug delivery systems, and to inspire further innovations in silica nanomedicine in the future.

Keywords: Biocompatibility; Combination therapy; Mesoporous silica nanoparticles (MSNs); Stimuli-responsive release.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Drug Delivery Systems*
Humans
Nanoparticles* / chemistry
Nanoparticles* / therapeutic use
Neoplasms* / drug therapy
Neoplasms* / metabolism
Neoplasms* / pathology
Porosity
Silicon Dioxide* / chemistry
Silicon Dioxide* / therapeutic use

Substances

Silicon Dioxide